English | 繁體

Search in the results

UM

Browse/Search Results:  1-9 of 9 Help

Selected(0)Clear Items/Page:    Sort:
Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma Journal article
Zhang, Qi Yi, Ding, Wen, Mo, Jian Shan, Ou-yang, Shu Min, Lin, Zi You, Peng, Ke Ren, Liu, Guo Pin, Lu, Jin Jian, Yue, Pei Bin, Lei, Jin Ping, Wang, Yan Dong, Zhang, Xiao Lei. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma[J]. ACTA PHARMACOLOGICA SINICA, 2024.
Authors:  Zhang, Qi Yi;  Ding, Wen;  Mo, Jian Shan;  Ou-yang, Shu Min;  Lin, Zi You; et al.
Favorite | TC[WOS]:5 TC[Scopus]:6  IF:6.9/7.6 | Submit date：2024/05/16
Acquired Sorafenib-resistance  Antisense Oligonucleotide  Hepatocellular Carcinoma  Stat3  
Ferroptosis inhibitor alleviates sorafenib-induced cardiotoxicity by attenuating KLF11-mediated FSP1-dependent ferroptosis Journal article
Li, Yilan, Yan, Jingru, Sun, Heng, Liang, Yating, Zhao, Qianqian, Yu, Shan, Zhang, Yao. Ferroptosis inhibitor alleviates sorafenib-induced cardiotoxicity by attenuating KLF11-mediated FSP1-dependent ferroptosis[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2024, 20(7), 2622-2639.
Authors:  Li, Yilan;  Yan, Jingru;  Sun, Heng;  Liang, Yating;  Zhao, Qianqian; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:8.2/8.3 | Submit date：2024/06/05
Cardiotoxicity  Ferroptosis Inhibitor  Fsp1  Gpx4  Klf11  Sorafenib  
Targeting mitophagy as a novel therapeutic approach in liver cancer Journal article
Ji Feng, Jing Zhou, Yong Wu, Han-Ming Shen, Tao Peng, Guo-Dong Lu. Targeting mitophagy as a novel therapeutic approach in liver cancer[J]. Autophagy, 2022, 19(7), 2164-2165.
Authors:  Ji Feng;  Jing Zhou;  Yong Wu;  Han-Ming Shen;  Tao Peng; et al.
Favorite | TC[WOS]:8 TC[Scopus]:8  IF:14.6/16.8 | Submit date：2023/01/30
Canagliflozin  Glucose Restriction  Hcc  Mitophagy  Sorafenib  
Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer Journal article
Li, Han, Yu, You, Liu, Yi, Luo, Zhihong, Law, Betty Yuen Kwan, Zheng, Yi, Huang, Xing, Li, Wenhua. Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer[J]. Pharmacological Research, 2022, 182.
Authors:  Li, Han;  Yu, You;  Liu, Yi;  Luo, Zhihong;  Law, Betty Yuen Kwan; et al.
Favorite | TC[WOS]:49 TC[Scopus]:56  IF:9.1/9.0 | Submit date：2023/01/30
Apoptosis  Cancer  Ferroptosis  Sorafenib  Ursolic Acid  
The Application of Ferroptosis in Diseases Review article
2020
Authors:  Qiu, Yangmin;  Cao, Yue;  Cao, Wangjia;  Jia, Yifei;  Lu, Na
Favorite | TC[WOS]:272 TC[Scopus]:285  IF:9.1/9.0 | Submit date：2021/12/06
Cancer  Cell Death  Deferasirox (Pubchem Cid: 214348)  Deferoxamine (Pubchem Cid: 2973)  Erastin (Pubchem Cid: 11214940)  Ferroptosis  Ferrostatin-1 (Pubchem Cid: 4068248)  Iron Metabolism  Lapatinib (Pubchem Cid: 208908)  Lipid Peroxidation  Ras-selective Lethal 3 (Pubchem Cid: 1750826)  Reactive Oxygen Species  Sorafenib (Pubchem Cid: 216239)  
Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration Journal article
Xia, Yijun, Yan, Wei, Guo, Libin, Meng, Chen, Li, Bin, Neves, Henrique, Chen, Peng-Chen, Li, Ling, Huang, Yide, Kwok, Hang Fai, Lin, Yao. Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration[J]. MOLECULAR MEDICINE REPORTS, 2017, 15(2), 941-947.
Authors:  Xia, Yijun;  Yan, Wei;  Guo, Libin;  Meng, Chen;  Li, Bin; et al.
Favorite | TC[WOS]:11 TC[Scopus]:11  IF:3.4/3.0 | Submit date：2018/10/30
Hepatocellular Carcinoma  Sorafenib  Digitoxin  Synergistic Inhibition  
Digitoxin Synergized with Sorafenib to Inhibit Hepatocelluar Carcinoma Cell Growth, but not Migration Journal article
Xiao, Y., Yan, W., Guo, L., Meng, C., Li, B., Neves, H., Chen, P., Li, L., Huang, Y., Kwok, H. F., Lin, Y.. Digitoxin Synergized with Sorafenib to Inhibit Hepatocelluar Carcinoma Cell Growth, but not Migration[J]. Molecular Medicine Reports, 2016, 941-947.
Authors:  Xiao, Y.;  Yan, W.;  Guo, L.;  Meng, C.;  Li, B.; et al.
Favorite | TC[WOS]:11 TC[Scopus]:11  IF:3.4/3.0 | Submit date：2022/06/02
Hepatocellular Carcinoma  Sorafenib  Digitoxin  Synergistic Inhibition  
Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3 Journal article
Zhaoxia Zou, Yufang Yin, Jenny Lin, Li-chen J. Hsu, Vanessa L. Brandon, Fan Yang, Richard Jove, Rahul Jandial, Gang Li, Mike Y. Chen. Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3[J]. JOURNAL OF NEUROSURGERY, 2016, 124(5), 1310-1318.
Authors:  Zhaoxia Zou;  Yufang Yin;  Jenny Lin;  Li-chen J. Hsu;  Vanessa L. Brandon; et al.
Favorite | TC[WOS]:5 TC[Scopus]:5  IF:3.5/4.1 | Submit date：2019/01/21
Sorafenib  Convection-enhanced Delivery  Stat3  Melanoma  Brain  Mice  Oncology  
iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy Journal article
Zhang J., Hu J., Chan H.F., Skibba M., Liang G., Chen M.. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy[J]. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12(5), 1303.
Authors:  Zhang J.;  Hu J.;  Chan H.F.;  Skibba M.;  Liang G.; et al.
Favorite | TC[WOS]:95 TC[Scopus]:105 | Submit date：2018/10/30
Active Targeting  Doxorubicin  Hepatocellular Carcinoma  Irgd Peptide  Sorafenib